Sonoma Pharmaceuticals Reports 18% Revenue Increase to $4.015 Million for Q2 2025

Sonoma Pharmaceuticals, Inc. reported a revenue of $4.015 million for the three months ended June 30, 2025, marking an 18% increase from $3.391 million in the same period last year. The company's gross profit also rose to $1.464 million, up 12% from $1.306 million, although the gross profit margin decreased slightly to 36% from 39%. The net loss for the quarter was $1.241 million, compared to a loss of $1.143 million in the prior year, resulting in a net loss per share of $0.76, an improvement from $1.34 per share in the previous year.

In terms of operational metrics, Sonoma's cash and cash equivalents decreased to $3.605 million from $5.374 million at the end of the previous quarter. The company reported an increase in accounts receivable, which rose to $2.602 million from $2.232 million, and inventories increased to $3.802 million from $2.915 million. The total current assets stood at $13.107 million, up from $12.648 million, while total liabilities increased to $10.538 million from $9.282 million, reflecting a growing operational scale.

Strategically, Sonoma has focused on expanding its product offerings and market reach. The company relaunched its prescription and office dispense dermatology products in December 2024 and introduced new consumer products, including LumacynTM Clarifying Mist in January 2024. Additionally, Sonoma entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of its Microcyn® technology-based products to large retailers in the U.S. This agreement is set for an initial term of two years with automatic renewal options.

Geographically, revenue from the United States increased by 57% to $1.005 million, while Europe saw a 14% rise to $1.468 million. Revenue from Asia grew by 39% to $662,000, but Latin America experienced a decline of 36% to $564,000, primarily due to timing of customer orders. The company continues to sell its products in 55 countries, leveraging both direct sales and partnerships with distributors.

Looking ahead, Sonoma Pharmaceuticals acknowledges the challenges of securing additional capital and the potential impact of economic conditions on its operations. The company is exploring various financing options, including public or private equity offerings and corporate collaborations. Management remains optimistic about the future, emphasizing the importance of product commercialization and market penetration to achieve its business objectives. However, there is substantial doubt about the company's ability to continue as a going concern if it cannot secure additional financing.